PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day mo

Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) wit

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and

Stocks slid as the 10-year Treasury yield hit a 19-year high on blowout PMI data; cybersecurity stoc

Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interfere

Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Con

Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data fro

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced in

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare C

Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rat

The transaction was valued at $1 million. The sale reduced the director's direct equity holdings by

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

Benjamin Edwards Inc. purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasir

Arrowhead Pharmaceuticals NASDAQ: ARWR presented 12-month results from its Phase 3 SHASTA-3 and SHAS

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and mai

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHAST

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHAS

PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new dat

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced th

Deutsche Bank AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the unde

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyc

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analy

SNDA to seek approval to expand the approved indication to include patients with severe hypertriglyc

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in t

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and

Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreati

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday&#39

Stocks split as oil climbs on the 11th night of Iran strikes and Super Micro rockets 26% on a record

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than

Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Phar

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday&#

Statistically significant reduction in acute pancreatitis events versus placebo across the entire sH

JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and rais